Alloreactive T Cell Depletion Method For Preventing Graft-Versus-Host Disease


The invention relates to the use of adenosine to deplete alloreactive T cells from donor grafts to prevent graft-versus-host disease (GVHD). The method includes culturing donor cells that include T cells with recipient antigen presenting cells (APCs) to form a mixture of cells. The recipient’s APCs activate donor T cells. The activated T cells are treated with high doses of adenosine or an adenosine-like molecule to decrease or inhibit viability of the activated donor T-cells. The adenosine or adenosine-like molecule is filtered away from the mixture resulting in cells that can be transplanted into the recipient.

Potential Commercial Applications: Competitive Advantages:
  • Transplantation rejection prevention
  • Graft-versus-Host disease
 
  • T cell selective
  • Non invasive


Development Stage:
Early-stage

Inventors:

Dhanalakshmi Chinnasamy (NHLBI)  ➽ more inventions...

John Barrett (NHLBI)  ➽ more inventions...

Gregory Whitehill (NHLBI)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 62/153,174 issued 2015-04-27
PCT Application No. PCT/US2016/029333

Licensing Contact:
Michael Shmilovich, J.D.
Email: shmilovm@mail.nih.gov
Phone: 301-435-5019

OTT Reference No: E-125-2015-0
Updated: May 14, 2018